Pfizer says its experimental antibiotic combo can deal with some superbug infections – ET HealthWorld

Pfizer says its experimental antibiotic combo can deal with some superbug infections – ET HealthWorld

New Delhi: Pfizer Inc mentioned on Thursday information from late-stage trials confirmed its experimental mixture of antibiotics was efficient in treating lethal infections attributable to drug-resistant micro organism.

Deaths from antibiotic-resistant micro organism, also referred to as superbugs, have been on the rise globally, and well being regulators have referred to as for the event of newer remedies as resistance to older antibiotics grows.

The late-stage research in contrast the experimental mixture of the antibiotics aztreonam-avibactam (ATM-AVI) and present generic drug metronidazole with a mixture of two older antibiotics – meropenem and colistin – to deal with sophisticated intra-abdominal infections and sorts of hospital-acquired pneumonia.

Hospital-acquired pneumonia happens in sufferers not less than two to 3 days after being admitted, or in those that have life-threatening lung infections with excessive mortality charges and who’re on mechanical respiratory machines.

Pfizer mentioned the information from the research exhibits the antibiotic mixture of ATM-AVI is efficient and well-tolerated in treating infections attributable to gram-negative micro organism.

The treatment price in sufferers with sophisticated intra-abdominal infections with Pfizer’s mixture remedy, together with present generic drug metronidazole, was 76.4 per cent, versus 74 per cent utilizing the opposite antibiotics.

For sufferers with sorts of hospital-acquired pneumonia and ventilator‐related pneumonia, the treatment price was 45.9 per cent for Pfizer’s antibiotic mixture with metronidazole, versus 41.7 per cent for different, older remedies.

The Facilities for Illness Management and Prevention estimates that 2.8 million antimicrobial-resistant infections happen every year in the USA.

  • Revealed On Jun 2, 2023 at 01:30 PM IST

Be part of the neighborhood of 2M+ trade professionals

Subscribe to our e-newsletter to get newest insights & evaluation.

Obtain ETHealthworld App

  • Get Realtime updates
  • Save your favorite articles

Scan to obtain App

Supply hyperlink


Please enter your comment!
Please enter your name here